prevailing price or post manufacturing, expenses charged are unreasonably high, the concerned manufacturers are asked to justify and if justification is not reasonable an attempt is made to prevail upon them to reduce the price to the extent possible.

Price fixation of and T.B. drugs

1902. SHRIMATI KAILASHPATI: Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that cases of wrong price fixation in case of anti-T.B. bulk drugs and getting data for cost study from companies like Ranbaxy have not been followed up;

(b) in what manner these companies are overcharging the prices of their bulk drugs and formulations and the reasons for not taking action against them;

(c) what is the reason for M/s Hoechst and M/s Glaxo keeping a number of their bulk drugs and formulations out-side price control; and

(d) whether compliants have been ignored and investigations in this area have not been held, if so, the reasons therefore?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) There is no case of wrong price fixation in case of Anti-T.B. drugs. To the extent information available, M/s. Ranbaxy does not manufacture Anti-T.B. drugs like Ethambutol, Rifamicin, Isoniazied, Thraoetazone, Sod PAS etc.

(b) Does not arise.

(c) to (d) Decision in regard to productmix to be manufactured by any company including M/s Hoechst and M/s Glaxo is dependent upon the corporate policy of that company and Government cannot interfere in the matter.

Identification of products marketed without approval

1903. SHRIMATI KAILASHPATI: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 375 given in the Rajya Sabha on 25th February, 1993 and state:

(a) what is the fate of the hearing by the regular bench in the case of Carews and whether it is a fact that in 1984 the company submitted applications for all its products to the Assistant Development Commissioner (PI);

(b) whether it is a fact that even after a lapse of eight years Government have failed to identify the products which have been marked without price approval and also to fix responsibility on the concerned officers;

(c) what is the stage of the investigation relating to inter connection of this company with Hoechst/B.B. Group stands and the reason for non-completion of investigation in spite of lapse of over three years; and

(d) whether it is a fact that M/s. Carews is merely a sham created to evade taxes and make money by tampering with purchase of raw materials?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) The matter is still pending in the Court. As per the record available no application for price fixation was submitted by M/s. Carews in 1984.

(b) For three formulations viz. (i) Combiflam Tabs; (ii) Carelgin Tabs. and (iii) Aleagel Tabs., prices were fixed on the basis of application submitted by M/s. Carews in 1986. To the extent information is available, for the other three products namely (i) Carovin Tonic; (ii) Carewvit Liquid; and (iii) Trimazol Tabs, the company does not appear to have obtained any price approval from the Government.

(c) The Department of Company Fertilizers has submitted a proposal to

have yet to take a final view in the matter.

(d) This Department has no information in this regard.

Duty reductions without cost benefit analysis

1904. SHRIMATI KAILASHPATI: Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that in a swift move Government propose to hike duty on intermediates;

(b) whether it is a fact that swift duty reduction without cost benefit analysis have affected domestic production from basrc stages;

(c) whether it is a fact that duty concessions have been given in the past two years without any cost benefit analysis;

(d) what steps are being taken to allow duty concessions only after a thorough study; and

(e) what steps have been taken to order an enquiry into the whole affairs?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) to (e) Recent changes in the customs duty structure are in line with the general approach of the Government, based on the Chelliah Committee's recommendations, of moving to regime of low to moderate customs duties which is considered essential for efficient and competitive industrialisation.

Non-inclusion of drugs under price control

1905. SHRIMATI KAILASHPATI: Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that Government have notified that drugs having turnoer of more than Rs. 50 lakhs, would be included under price control till review of policy, if so, authority which passed such order;

(b) whether Cefotaxim, Ceftazidime, glybenclamide and Cefadroxil are outside price control if so, the reasons therefor;

(c) whether it is a fact that over 50 to 60 drugs which should have been included under price control have been kept outside price control;

(d) whether it is a fact that this amounts to discrimination as well as bias against drugs produced domestically;

(e) whether it is a fact that new drugs are kept outside price control and the older drugs are under price control; and

(f) what are the names of such drugs having turn over of more than two crores per annum?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) No, Sir. There is no such notification.

(b) Yes, Sir. Drugs kept under price control are in accordance with the consultation with the Ministry of Health in regard to Category I and in accordance with the recommendation of Kelkar Committee in regard to Category II, as provided for in Drug Policy, 1986.

(c) to (f) The matter relating to inclusion/exclusion of drugs under price control is part of the Review of Drug Policy '86 and a Background Note for discussion has been placed on the Table of the House on 12.8.1992.

Additional profits to fertiliser industry

1906. SHRI SOM PAL:
SHRI SARADA MOHANTY:
DR. NAUNIHAL SINGH:
SHRI RAM GOPAL YADAV:

Will the PRIME MINISTER be pleased to state:

(a) whether Ministry of Chemicals and Fertilizers has submitted a a pcoposal to